Iyer L, Ratain M J
Committee on Clinical Pharmacology, University of Chicago, IL 60637, USA.
Cancer Chemother Pharmacol. 1998;42 Suppl:S31-43. doi: 10.1007/s002800051077.
Camptothecins (CPTs) are a unique class of chemotherapeutic agent which inhibit DNA synthesis by inhibiting topoisomerase I activity. Structure-activity studies on the original CPT alkaloid led to the development of the new analogues irinotecan (CPT-11), topotecan, and 9-aminocamptothecin, which have improved water solubility and lower toxicity. CPT analogues exhibit interesting pharmacokinetic/pharmacodynamic and metabolic properties that are of major research and clinical interest. This review describes the clinical pharmacology of these 3 CPT analogues. Specific areas such as absorption after extravascular administration, pharmacokinetic/pharmacodynamic variability, metabolism, and administration in special populations are discussed.
喜树碱(CPTs)是一类独特的化疗药物,通过抑制拓扑异构酶I的活性来抑制DNA合成。对原始喜树碱生物碱的构效关系研究导致了新的类似物伊立替康(CPT-11)、拓扑替康和9-氨基喜树碱的开发,这些类似物具有改善的水溶性和更低的毒性。喜树碱类似物表现出有趣的药代动力学/药效学和代谢特性,这是主要的研究和临床关注点。本综述描述了这三种喜树碱类似物的临床药理学。讨论了诸如血管外给药后的吸收、药代动力学/药效学变异性、代谢以及特殊人群给药等特定领域。